Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.
Description: The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19
Measure: Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19 Time: 2 weeks after the second dose of vaccinationDescription: The protection rate of, at least, one dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19 Two weeks after the last dose vaccination.
Measure: Protection Indexes of One Vaccine Dose For Symptomatic COVID-19 Time: 2 weeks after the second dose of vaccinationDescription: The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against rates of hospitalization, disease severity/and death two weeks after the second dose of vaccination
Measure: Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death Time: 2 weeks after the second dose of vaccinationDescription: The protection rate of a two dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed SARS-CoV-2 infection two weeks after the second dose of vaccination
Measure: Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection Time: 2 weeks after the second dose of vaccinationDescription: The incidence of adverse reactions from the day of first vaccination to 28 days after the second dose of vaccination.
Measure: Safety indexes of adverse reactions in 28 days Time: 28 days after the second dose of vaccinationDescription: The incidence of adverse reactions within 7 days after each dose of vaccination
Measure: Safety indexes of adverse reactions in 7 days Time: 7 days after each dose of vaccinationDescription: The incidence of SAEs from the first vaccination to one year after the second dose vaccination
Measure: Safety indexes of serious adverse events in 1 year Time: 1 year after second dose of vaccinationDescription: The seroconversion rate, seropositivity rate 14 days after each dose vaccination
Measure: Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days Time: 14 days after each dose vaccinationDescription: The seroconversion rate, seropositive rate 28 days after the second dose vaccination
Measure: Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days Time: 28 days after the second dose vaccinationDescription: GMT and GMI of neutralizing antibody and IgG 14 days after each dose vaccination
Measure: Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days Time: 14 days after each dose vaccinationDescription: GMT and GMI of neutralizing antibody and IgG 28 days after the second dose vaccination
Measure: Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days Time: 28 days after the second dose vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports